XtalPi Holdings (2228.HK) is rapidly commercializing its AI-for-Science platform, with recent partnerships, platform upgrades, and an FDA IND filing for its pan-TRK inhibitor. The chairman announced plans to increase his stake by up to HK$32 million, reinforcing confidence.
XtalPi is a high-growth AI drug discovery play with strong insider conviction and multiple near-term catalysts, but execution risks remain.
Free preview — more China A-share & HK research · About Us · Legal & Privacy